

Seamus Kent

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1099977/publications.pdf>

Version: 2024-02-01

21
papers

841
citations

623734

14
h-index

713466

21
g-index

21
all docs

21
docs citations

21
times ranked

1775
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Application of quantitative bias analysis for unmeasured confounding in cost-effectiveness modelling. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 861-870. | 1.4 | 4 |
| 2 | Does bariatric surgery reduce future hospital costs? A propensity score-matched analysis using UK Biobank Study data. <i>International Journal of Obesity</i> , 2021, 45, 2205-2213. | 3.4 | 2 |
| 3 | The use of nonrandomized evidence to estimate treatment effects in health technology assessment. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1035-1043. | 1.4 | 18 |
| 4 | Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment. <i>Pharmacoeconomics</i> , 2021, 39, 275-285. | 3.3 | 42 |
| 5 | Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. <i>Lancet Rheumatology</i> , The, 2020, 2, e698-e711. | 3.9 | 117 |
| 6 | BMI and Cause-Specific Hospital Admissions and Costs: The UK Biobank Cohort Study. <i>Obesity</i> , 2020, 28, 1332-1341. | 3.0 | 9 |
| 7 | Total versus partial knee replacement in patients with medial compartment knee osteoarthritis: the TOPKAT RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-98. | 2.8 | 27 |
| 8 | Outpatient physiotherapy versus home-based rehabilitation for patients at risk of poor outcomes after knee arthroplasty: CORKA RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-116. | 2.8 | 62 |
| 9 | The clinical and cost-effectiveness of total versus partial knee replacement in patients with medial compartment osteoarthritis (TOPKAT): 5-year outcomes of a randomised controlled trial. <i>Lancet</i> , The, 2019, 394, 746-756. | 13.7 | 195 |
| 10 | The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. <i>Pharmacoeconomics</i> , 2019, 37, 1305-1312. | 3.3 | 28 |
| 11 | Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. <i>Kidney International</i> , 2019, 96, 170-179. | 5.2 | 13 |
| 12 | Is Doctor Referral to a Low-Energy Total Diet Replacement Program Cost-Effective for the Routine Treatment of Obesity?. <i>Obesity</i> , 2019, 27, 391-398. | 3.0 | 20 |
| 13 | Body mass index and use and costs of primary care services among women aged 55-79 years in England: a cohort and linked data study. <i>International Journal of Obesity</i> , 2019, 43, 1839-1848. | 3.4 | 11 |
| 14 | Hospital costs in relation to body-mass index in 1.1 million women in England: a prospective cohort study. <i>Lancet Public Health</i> , The, 2017, 2, e214-e222. | 10.0 | 30 |
| 15 | Body mass index and healthcare costs: a systematic literature review of individual participant data studies. <i>Obesity Reviews</i> , 2017, 18, 869-879. | 6.5 | 91 |
| 16 | A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. <i>Heart</i> , 2017, 103, 1880-1890. | 2.9 | 21 |
| 17 | Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 348-354. | 2.2 | 8 |
| 18 | Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). <i>American Journal of Kidney Diseases</i> , 2016, 67, 576-584. | 1.9 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. BMC Nephrology, 2015, 16, 65. | 1.8 | 82 |
| 20 | Mapping from the Parkinsonâ€™s Disease Questionnaire PDQ-39 to the Generic EuroQol EQ-5D-3L. Medical Decision Making, 2015, 35, 902-911. | 2.4 | 26 |
| 21 | ARE VALUE OF INFORMATION METHODS READY FOR PRIME TIME? AN APPLICATION TO ALTERNATIVE TREATMENT STRATEGIES FOR NSTEMI PATIENTS. International Journal of Technology Assessment in Health Care, 2013, 29, 435-442. | 0.5 | 16 |